Electronic Resource
Treatment Options for Resistant Kawasaki Disease.
| العنوان: | Treatment Options for Resistant Kawasaki Disease. |
|---|---|
| المؤلفون: | Burgner D., Phuong L.K., Gowdie P., Curtis N., Akikusa J. |
| بيانات النشر: | Springer International Publishing Switzerland 2018-01-30 |
| نوع الوثيقة: | Electronic Resource |
| مستخلص: | "Resistant" Kawasaki disease is defined by the American Heart Association as failure to respond within 36 h following the first dose of intravenous immunoglobulin. The optimal management of resistant Kawasaki disease remains uncertain, the outcomes are potentially serious, and the cost of some treatments is considerable. We review the current evidence to guide treatment of resistant Kawasaki disease. Given the relative rarity, there are few trial data, and studies tend to be small and methodologically heterogeneous, making interpretation difficult and limiting generalisability. The literature on resistant Kawasaki disease should be interpreted with reference to current expert consensus guidelines.Copyright © 2017, Springer International Publishing AG. |
| مصطلحات الفهرس: | human, methodology, mucocutaneous lymph node syndrome/dr [Drug Resistance], mucocutaneous lymph node syndrome/dt [Drug Therapy], mucocutaneous lymph node syndrome/th [Therapy], plasma exchange, practice guideline, priority journal, treatment planning, acetylsalicylic acid/dt [Drug Therapy], anakinra/dt [Drug Therapy], biological product/dt [Drug Therapy], chlorpheniramine/dt [Drug Therapy], corticosteroid/dt [Drug Therapy], cyclosporine/dt [Drug Therapy], cytotoxic agent/dt [Drug Therapy], diphenhydramine/dt [Drug Therapy], heparin/dt [Drug Therapy], immunoglobulin/dt [Drug Therapy], infliximab/dt [Drug Therapy], methotrexate/dt [Drug Therapy], methylprednisolone/dt [Drug Therapy], paracetamol/dt [Drug Therapy], prednisolone/dt [Drug Therapy], rituximab/dt [Drug Therapy], steroid/dt [Drug Therapy], tumor necrosis factor inhibitor/dt [Drug Therapy], ulinastatin/dt [Drug Therapy], review, combination chemotherapy, disease classification, drug treatment failure, Review |
| URL: | Pediatric Drugs Click here for full text options LibKey Link |
| الاتاحة: | Open access content. Open access content Copyright 2018 Elsevier B.V., All rights reserved. |
| Other Numbers: | AUSHL oai:repository.monashhealth.org:1/38499 Pediatric Drugs. 20 (1) (pp 59-80), 2018. Date of Publication: 01 Feb 2018. 1174-5878 https://repository.monashhealth.org/monashhealthjspui/handle/1/38499 Burgner, David; ORCID: http://orcid.org/0000-0002-8304-4302 29101553 [http://www.ncbi.nlm.nih.gov/pubmed/?term=29101553] 619094574 (Phuong, Curtis) Infectious Diseases Unit, Royal Children's Hospital Melbourne, Parkville, Australia (Curtis, Burgner) Department of Paediatrics, The University of Melbourne, Parkville, Australia (Gowdie, Akikusa) Rheumatology Service, Department of General Medicine, Royal Children's Hospital, Melbourne, Australia (Gowdie) Department of Paediatrics and Department of Paediatric Rheumatology, Monash Children's Hospital, Clayton, Australia (Gowdie, Burgner) Department of Paediatrics, Monash University, Melbourne, Australia (Akikusa, Burgner) Murdoch Children's Research Institute, Royal Children's Hospital Melbourne, Flemington Road, Parkville, VIC 3052, Australia Burgner D.; david.burgner@mcri.edu.au 1305133031 |
| المصدر المساهم: | MONASH HEALTH LIBRS From OAIster®, provided by the OCLC Cooperative. |
| رقم الانضمام: | edsoai.on1305133031 |
| قاعدة البيانات: | OAIster |
| الوصف غير متاح. |